Parkinson's Disease

• Substantia nigra pars compacta (SNpc) neuronal loss with Lewy body formation: The primary pathological hallmark is selective degeneration of dopaminergic neurons projecting from the SNpc to the putamen (a key component of the basal ganglia). Histologically, surviving neurons contain Lewy bodies—intracytoplasmic inclusions composed primarily of α-synuclein, a presynaptic protein involved in synaptic vesicle dynamics. The pathological cascade begins with misfolding and accumulation of α-synuclein, which propagates in a prion-like manner, oligomerizes, and triggers neuroinflammatory responses with microglial activation. Neuronal loss is progressive: by the time motor symptoms emerge, approximately 50-60% of SNpc dopaminergic neurons have been lost, and 70-80% loss occurs in advanced disease. This explains the delayed clinical manifestation relative to underlying pathology and the eventual motor plateau despite continued neuronal loss.

• Disruption of direct vs. indirect motor circuits causing hypokinesia: Normal basal ganglia motor circuits depend on balanced activity between the direct pathway (facilitates movement: striatum → globus pallidus interna [GPi]/substantia nigra pars reticulata [SNpr] → thalamus) and the indirect pathway (inhibits movement: striatum → globus pallidus externa [GPe] → subthalamic nucleus [STN] → GPi/SNpr → thalamus). The direct pathway is tonically suppressed by dopamine deficiency (dopamine receptors on direct pathway neurons are D1 receptors, which are excitatory), while the indirect pathway becomes relatively overactive due to loss of dopamine-mediated inhibition of GPe neurons (which express D2 receptors). This creates pathological overactivity of STN and GPi output, increasing inhibitory GABAergic thalamic input and reducing cortical motor drive. The resulting net effect is hypokinesia (reduced movement initiation and amplitude), explaining bradykinesia and the difficulty initiating voluntary movement despite intact motor cortices and motor neurons.

• Progressive non-dopaminergic neurodegeneration throughout distributed networks: While dopaminergic loss in SNpc is the most prominent feature, Lewy body pathology extends beyond midbrain dopaminergic systems to affect serotonergic neurons in the dorsal raphe nucleus, noradrenergic neurons in the locus coeruleus, and cholinergic neurons in the pedunculopontine nucleus. Additionally, α-synuclein pathology affects cortical regions, amygdala, and autonomic nervous system nuclei. This distributed pathology underlies non-motor symptoms including depression (serotonin and noradrenaline), cognitive decline and dementia (cortical involvement), autonomic dysfunction (sympathetic and parasympathetic denervation), and REM sleep behavior disorder (pedunculopontine and pontine involvement). The Braak hypothesis proposes rostral spread of pathology from lower brainstem/olfactory bulb through midbrain to cortex, explaining the temporal evolution of both motor and non-motor manifestations.

• Genetic and protein-trafficking mechanisms in selective neuronal vulnerability: While most PD cases are sporadic, identified genetic mutations (SNCA, LRRK2, PARK2, PINK1, DJ-1) and genome-wide association studies reveal that disrupted protein quality control is central to pathogenesis. Mitochondrial dysfunction plays a crucial role: complex I of the electron transport chain is particularly vulnerable, and impaired oxidative phosphorylation increases reactive oxygen species (ROS) production. The resulting oxidative stress overwhelms protective mechanisms and promotes α-synuclein oxidation and aggregation. Additionally, impaired autophagy-lysosomal pathway (especially autophagy and chaperone-mediated autophagy) reduces clearance of misfolded α-synuclein. Proteasomal dysfunction and alterations in ubiquitin-proteasome system efficiency further compromise protein degradation. Dopaminergic neurons are particularly vulnerable because dopamine metabolism itself generates ROS through monoamine oxidase-B (MAO-B) oxidation, and dopamine can form neurotoxic quinone metabolites that covalently modify proteins. Genetic polymorphisms in genes affecting mitochondrial function, α-synuclein processing, and autophagy determine individual susceptibility.

• Loss of trophic factors and neuroinflammation: Reduction in glial cell line-derived neurotrophic factor (GDNF) and other neurotrophic factors impairs neuronal survival signaling. Concurrently, α-synuclein aggregates activate pattern recognition receptors on microglia and astrocytes, triggering release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and chemokines that perpetuate neurodegeneration through complement activation, oxidative stress, and toxic metabolite production. This neuroinflammatory cascade becomes self-perpetuating and contributes to progressive loss of remaining dopaminergic neurons.

• Idiopathic Parkinson's disease (sporadic, ~85-90% of cases): Represents the vast majority of PD cases with no clear monogenic cause. Age is the strongest non-genetic risk factor, with exponential increase in incidence after age 60. Environmental exposures implicated include pesticides (paraquat, rotenone—complex I inhibitors mimicking MPTP toxicity), heavy metals (manganese, lead), organic solvents, and head trauma with loss of consciousness. Epidemiological evidence supports an association with rural living and pesticide exposure, though causation remains unproven. The "two-hit" hypothesis suggests that genetic predisposition (variations affecting dopaminergic neuron vulnerability) combined with environmental exposures over decades triggers disease.

• Monogenic familial Parkinson's disease: Approximately 5-10% of cases have clear autosomal dominant (SNCA, LRRK2) or autosomal recessive inheritance (PARK2/parkin, PINK1, DJ-1). SNCA mutations (α-synuclein gene duplications/triplications and missense mutations) cause dominantly inherited disease with early onset (30s-40s) and aggressive course. LRRK2 mutations (particularly the G2019S variant, common in Ashkenazi Jewish and North African populations) cause late-onset parkinsonism clinically indistinguishable from sporadic PD but with reduced penetrance (~30-40%). Autosomal recessive mutations (PARK2/parkin, PINK1, DJ-1) cause early-onset parkinsonism (before age 40) with slower progression, more prominent dystonia, and less prominent tremor. Young-onset cases should prompt genetic counseling and testing.

• Secondary parkinsonism from specific etiologies: Drug-induced parkinsonism (antipsychotics—D2 blockers; metoclopramide; some antiemetics; lithium; calcium channel blockers) is the most common cause of parkinsonism overall and may be reversible if medications discontinued early. Vascular parkinsonism results from multiple subcortical infarcts affecting basal ganglia and motor circuits, presenting with prominent lower-body parkinsonism and gait dysfunction ("lower-body parkinsonism"). Parkinsonism-plus syndromes (atypical parkinsonian disorders) include progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple system atrophy (MSA), and Lewy body dementia (LBD)—these present with parkinsonism plus additional features (vertical gaze palsy in PSP, alien limb in CBD, prominent autonomic failure in MSA, early dementia in LBD) and generally show poor or absent dopaminergic response. Toxin-induced parkinsonism (MPTP—seen in illicit drug users; manganese; carbon monoxide) can cause irreversible damage. Normal pressure hydrocephalus presents with the classic triad of gait disturbance ("magnetic" gait), cognitive decline, and urinary incontinence; MRI shows ventricular enlargement out of proportion to sulcal atrophy.

• Risk modifiers and protective factors: Smoking and caffeine consumption appear protective (possibly through MAO-B inhibition or other mechanisms, though reverse causality cannot be excluded). Physical activity appears protective. Estrogen exposure in women may be neuroprotective, with some studies showing lower risk in hormone replacement therapy users.

Motor cardinal features

• Resting tremor (4-6 Hz) is the most visible symptom, present in ~70% at diagnosis. Characteristically low-frequency, high-amplitude tremor most prominent at rest and diminishing with action (distinguishing it from essential tremor, which worsens with intentional movement). The classic "pill-rolling" tremor involves thumb and fingers. Tremor is often the first symptom noticed by patients or family. Neurophysiologically, tremor results from oscillatory activity between thalamus and basal ganglia output nuclei due to loss of dopaminergic modulation.

• Bradykinesia (slowing of movement) and hypokinesia (reduced amplitude of movement) are the most cardinal and functionally disabling features, present in nearly 100% of PD patients and required for diagnosis. Manifests as slowed speech (hypophonia—soft, monotone voice), slowed writing with progressive micrographia (small, cramped handwriting), slow deliberate movements, prolonged reaction time, and difficulty with rapid alternating movements. Physiologically reflects the pathological overactivity of GPi/SNpr output from disrupted direct/indirect pathway balance. Critically, bradykinesia may worsen with fatigue and emotional stress and is often most pronounced in the afternoon ("end-of-dose" deterioration during medication waning).

• Rigidity (increased tone throughout movement range, present in ~80% at diagnosis) appears as resistance to passive movement in both flexion and extension, described as "lead pipe" rigidity when smooth, or "cogwheel" rigidity when superimposed tremor creates a ratcheting sensation. Rigidity typically affects axial (neck, trunk) and proximal (hip, shoulder) muscles more than distal muscles, contributing to stooped posture. Unlike spasticity (upper motor neuron lesion), rigidity is present throughout movement with no clasp-knife phenomenon.

Postural and gait abnormalities

• Postural instability and loss of postural reflexes develop later (typically 5-10+ years into disease) and severely impact quality of life. Loss of righting reflexes impairs ability to recover from perturbations; clinical testing reveals positive pull test (pulling backward on shoulders; normal is 1-2 steps backward recovery; abnormal is falling without stepping or inability to recover). Stooped posture with flexed knees, hips, and trunk (festinating posture) reflects rigidity and bradykinesia.

• Gait disturbance characterized by short, shuffling steps with reduced arm swing (hypokinetic gait). Freezing of gait (sudden, transient inability to initiate or continue stepping, as if feet are "glued to floor") develops in ~30% of patients and may be triggered by narrow spaces, crowds, or emotional stress; causes severe falls. Festination (involuntary acceleration of gait once initiated) also occurs. These gait abnormalities reflect involvement of pedunculopontine nucleus and brainstem locomotor regions beyond the dopaminergic SNpc.

• Cognitive decline and dementia: ~24-30% of PD patients develop Parkinson's disease dementia (PDD) within 10 years of motor symptom onset; an additional 25-30% have mild cognitive impairment. Presents with bradyphrenia (slowed thinking), executive dysfunction, visuospatial impairment, and attention deficits; memory is relatively spared early (distinguishing from Alzheimer's). Cortical Lewy body pathology underlies dementia risk.

• Psychiatric symptoms: Depression occurs in 30-40%, often preceding motor symptoms; presents atypically with apathy and bradyphrenia rather than mood complaint. Anxiety disorders (panic, generalized anxiety, social anxiety) in ~30%. Impulse control disorders (gambling, hypersexuality, compulsive shopping, binge eating) develop in 13-17%, particularly in patients on dopamine agonists. Psychosis (visual hallucinations, delusions) develops in advanced disease or with dopaminergic medications, particularly in those with dementia.

• Sleep disorders: REM sleep behavior disorder (RBD) (acting out dreams with motor activity during REM sleep) occurs in 25-50% of PD patients and may antedate motor symptoms by years; reflects pedunculopontine involvement. Insomnia from difficulty turning in bed due to rigidity, nocturia, restless leg syndrome, and sleep apnea common. Excessive daytime somnolence from non-motor pathology and medications.

• Autonomic dysfunction: Orthostatic hypotension (drop in systolic BP ≥20 mmHg or diastolic ≥10 mmHg upon standing) occurs in 30-60%, worsened by dopaminergic medications; increases falls and syncope risk. Urinary dysfunction (urgency, frequency, nocturia, incomplete emptying) in ~60%. Constipation (often severe, preceding motor symptoms) in ~60-70%, from both reduced gut motility and medications. Sexual dysfunction (erectile dysfunction in men, reduced libido, orgasmic difficulties in both sexes) in ~40-60%. Excessive salivation (sialorrhea) from difficulty swallowing saliva rather than increased production. Impaired thermoregulation (excessive sweating, cold extremities).

• Sensory symptoms: Pain (musculoskeletal from dystonia and rigidity, radicular, central neuropathic pain) in ~40-85%; often attributed to non-PD causes, delaying diagnosis. Olfactory dysfunction (hyposmia/anosmia) in ~90%, often precedes motor symptoms by years; useful diagnostic clue. Restless leg syndrome in ~20-30%. Paresthesias and dysesthesias.

Physical examination findings beyond cardinal triad

• Facial masking (reduced facial expression, decreased blink rate, "poker face") from facial bradykinesia; often mistaken for depression or apathy.

• Hypophonia and hypospeech (soft, monotone, rushed or irregular speech) from laryngeal bradykinesia and rigidity; may impair communication with examiner.

• Hypomimia combined with reduced blink rate (normal 15-20 blinks/min; PD often <5).

• Gait asymmetry at presentation, with one side often affected more than the other; many develop asymmetric parkinsonism throughout disease course.

• Atypical presentations: Akinetic-rigid subtype (hypokinesia and rigidity prominent, tremor absent in ~25% of patients) tends to have faster progression and higher dementia risk than tremor-dominant subtype. Young-onset PD (age <40-50) may present with dystonia-predominant features (foot dystonia, writer's cramp) or rapid progression with cognitive features.

• UK Parkinson's Disease Society Brain Bank criteria (most widely used for research; supports clinical diagnosis):
• **Step 1 - Parkinson

Acute issue to address first

• Never abruptly stop dopaminergic therapy (NPO status, surgery, missed doses): risks parkinsonism-hyperpyrexia syndrome, a neuroleptic malignant syndrome look-alike. Continue levodopa via enteral tube or substitute a rotigotine patch.

First-line therapy

• Levodopa/carbidopa (dopamine precursor plus peripheral AADC inhibitor): most effective agent for bradykinesia and rigidity. The AAN's 2021 guideline on early Parkinson disease supports levodopa as initial dopaminergic therapy, particularly in patients over ~60, accepting higher long-term dyskinesia risk for superior efficacy. Carbidopa does not cross the blood-brain barrier; it blocks peripheral conversion, reducing nausea and hypotension.
• MAO-B inhibitors (rasagiline, selegiline): modest monotherapy benefit in very mild disease.
• Dopamine agonists (pramipexole, ropinirole): alternative in younger patients to delay dyskinesia, but the AAN highlights higher rates of impulse control disorders, hallucinations, sleep attacks, and edema — avoid in the elderly or cognitively impaired.
• Anticholinergics (trihexyphenidyl) only for tremor-predominant young patients; amantadine (NMDA antagonist) for tremor and, notably, for dyskinesia.

Escalation for motor fluctuations

• Shorten dosing intervals; add COMT inhibitors (entacapone), MAO-B inhibitors, extended-release formulations, adenosine A2A antagonist istradefylline, inhaled levodopa, or levodopa–carbidopa intestinal gel.
• Subcutaneous apomorphine rescues "off" episodes but is contraindicated with 5-HT3 antagonists (ondansetron, granisetron, dolasetron) — the combination causes profound hypotension and syncope; use trimethobenzamide for apomorphine-related nausea. It is also a vasodilator: caution with nitrates and PDE-5 inhibitors.

Device/surgical therapy

• Deep brain stimulation of the subthalamic nucleus or globus pallidus interna for levodopa-responsive motor fluctuations/dyskinesia; requires preserved levodopa response and excludes dementia or uncontrolled psychiatric illness. Focused ultrasound thalamotomy targets refractory tremor.

Contraindicated / avoid

• D2 blockers — haloperidol, metoclopramide, prochlorperazine — worsen parkinsonism; ondansetron is preferred for nausea (except with apomorphine).
• For psychosis, avoid typical antipsychotics; use pimavanserin (boxed warning: increased mortality in elderly patients with dementia-related psychosis; QT prolongation), quetiapine, or clozapine (requires ANC monitoring for agranulocytosis). Rivastigmine is used for Parkinson disease dementia.
• MAO-B inhibitors with meperidine, tramadol, or linezolid (serotonin syndrome).

Disease-related

• Falls and hip fracture: loss of postural reflexes plus freezing of gait; a positive pull test or first fall predicts injury and signals advancing disease.
• Dysphagia and aspiration pneumonia: pharyngeal bradykinesia; wet voice, coughing with meals, recurrent lower-lobe infiltrates. Aspiration pneumonia is the leading cause of death in PD and is an emergency when it presents with sepsis or respiratory failure.
• Parkinson disease dementia: cortical Lewy body burden; executive/visuospatial decline with relatively spared early memory.
• Orthostatic hypotension: cardiac sympathetic denervation plus dopaminergic drugs; syncope and unexplained falls. Treated with nonpharmacologic measures, then midodrine, droxidopa, or fludrocortisone.
• Constipation, urinary retention, sialorrhea: enteric and autonomic α-synuclein pathology; obstipation can progress to ileus.

Treatment-related

• **Motor fluctuations (wearing-off, on–off phenomenon)**: as nigral terminals are lost, striatal dopamine storage capacity falls and the clinical effect tracks the plasma levodopa curve — benefit fades before the next dose.
• Peak-dose dyskinesia: pulsatile stimulation of supersensitive striatal receptors; choreiform writhing at maximal benefit. Treat by lowering the per-dose amount, adding amantadine, or DBS.
• Impulse control disorders (gambling, hypersexuality, compulsive shopping) and dopamine dysregulation syndrome: mesolimbic D3 stimulation, classically with dopamine agonists — ask about them explicitly, because patients rarely volunteer them.
• Hallucinations/psychosis: typically well-formed visual hallucinations; reduce anticholinergics, amantadine, then agonists before adding pimavanserin or quetiapine.
• Sudden-onset sleep attacks with agonists: counsel about driving.
• Parkinsonism-hyperpyrexia syndrome after abrupt dopaminergic withdrawal — fever, rigidity, altered mentation, elevated creatine kinase; an emergency managed with rehydration, cooling, and reinstitution of dopaminergic therapy.
• Serotonin syndrome with MAO-B inhibitors plus meperidine, tramadol, or linezolid — also an emergency.
• Minor drug effects: entacapone causes harmless orange-brown urine and diarrhea; amantadine causes livedo reticularis and ankle edema; anticholinergics cause confusion, urinary retention, and can precipitate angle-closure glaucoma.

• Asymmetric 4–6 Hz resting tremor that improves with action is PD; a bilateral action tremor improved by alcohol and treated with propranolol or primidone is essential tremor. This is the most common distractor pair.
• Bradykinesia is mandatory for the diagnosis; tremor is not. A tremorless akinetic-rigid presentation still qualifies and carries faster progression.
• Carbidopa does not cross the blood–brain barrier — it blocks peripheral aromatic L-amino acid decarboxylase, increasing CNS levodopa delivery and reducing nausea. Vitamin B6 (pyridoxine) accelerates peripheral decarboxylation; high-protein meals compete for the LAT1 transporter and blunt absorption.
• The single best next step when a patient with parkinsonism vomits or is agitated: choose ondansetron and quetiapine/pimavanserin — never metoclopramide, prochlorperazine, or haloperidol. The one exception: if the patient is on apomorphine, ondansetron is contraindicated (profound hypotension) — use trimethobenzamide.
• Symmetric parkinsonism with a recent antipsychotic, metoclopramide, or antiemetic = drug-induced parkinsonism, the most common cause of secondary parkinsonism (second only to idiopathic PD among all causes, and especially common in the elderly); the move is to stop the offending drug, not to start levodopa.
• The 1-year rule: dementia preceding or within one year of parkinsonism with fluctuating cognition, visual hallucinations, and severe neuroleptic sensitivity = dementia with Lewy bodies; dementia arising years after established motor disease = Parkinson disease dementia.
• Atypical parkinsonism red flags (poor levodopa response, early falls): vertical supranuclear gaze palsy = PSP; early severe autonomic failure with cerebellar signs = MSA; alien limb and asymmetric apraxia = corticobasal degeneration.
• REM sleep behavior disorder and hyposmia can precede motor onset by years — the classic prodromal association examiners test.
• Never abruptly discontinue levodopa in the perioperative or NPO patient: parkinsonism-hyperpyrexia syndrome mimics NMS.
• DBS targets the subthalamic nucleus or globus pallidus interna, and benefit generally mirrors the best levodopa response — tremor is the notable exception and may respond even when levodopa-refractory. DBS does not reliably improve levodopa-unresponsive axial freezing, postural instability, or cognition.